Insight

Sevinç Balli: Low dose Nivolumab maybe an option?

Sevinç Balli/researchgate.net

Apr 4, 2025, 17:22

Sevinç Balli: Low dose Nivolumab maybe an option?

Sevinç Balli, Medical Oncologist at Ankara University, shared JCO Global Oncology’s post on X:

“Low dose Nivolumab maybe an option?”

Quoting JCO Global Oncology’s post on X about a recent paper by Praveen Kumar Marimuthu et al. published in ASCO Publications:

“Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis”

Authors: Praveen Kumar Marimuthu et al.

Sevinç Balli

Ajoy Oommen John and Ashish Singh. Anjana Joel Aparna Irodi Balamugesh Thangakunam Balukrishna Sasidharan Barney T.J. Isaac cancer Deepa Susan Joy Philip Divya Bala Thumaty Jansi Rani JCO Global Oncology Josh Thomas Georgy Kovilapu Harikrishna Lung cancer Manu Mathew NSCLC OncoDaily Oncology Prashant Jambunathan Praveen Kumar Marimuthu Rajesh Isiah Raju Titus Chacko Richa Gupta Sevinc Balli Simon Pradeep Pavamani Thomas Alex Kodiatte Zachariah Thomas

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research